Nifty
Sensex
:
:
25285.35
82500.82
103.55 (0.41%)
328.72 (0.40%)

Pharmaceuticals & Drugs

Rating :
59/99

BSE: 543960 | NSE: CONCORDBIO

1603.00
10-Oct-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1588.1
  •  1627
  •  1579.2
  •  1590.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  168044
  •  267761238.7
  •  2451.7
  •  1345

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 16,743.30
  • 47.02
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 16,742.50
  • 0.67%
  • 9.02

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.08%
  • 1.75%
  • 7.77%
  • FII
  • DII
  • Others
  • 8.03%
  • 8.43%
  • 29.94%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.83
  • 14.23
  • 12.05

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.10
  • 9.10
  • 7.77

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.64
  • 9.57
  • 15.68

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Earnings Forecasts:

(Updated: 11-10-2025)
Description
2024
2025
2026
2027
Adj EPS
35.52
38.62
49.63
62.58
P/E Ratio
45.13
41.51
32.30
25.62
Revenue
1179.82
1401.47
1696.88
2057.46
EBITDA
498.13
565.84
711.92
875.12
Net Income
371.64
404.68
518.52
663.14
ROA
19.9
18.5
20.83
22.18
P/B Ratio
9.25
7.87
6.60
5.47
ROE
22.26
20
21.77
22.48
FCFF
136.09
340
412.71
508.68
FCFF Yield
0.81
2.03
2.46
3.03
Net Debt
-314.76
-215.25
-328.25
-467.2
BVPS
173.27
203.62
242.98
293.02

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
203.99
215.80
-5.47%
429.88
318.97
34.77%
244.22
240.80
1.42%
310.18
262.35
18.23%
Expenses
142.59
134.52
6.00%
239.46
184.68
29.66%
146.27
134.87
8.45%
173.50
143.16
21.19%
EBITDA
61.40
81.28
-24.46%
190.42
134.29
41.80%
97.95
105.93
-7.53%
136.68
119.19
14.67%
EBIDTM
30.10%
37.66%
44.30%
42.10%
40.11%
43.99%
44.06%
45.43%
Other Income
13.68
10.31
32.69%
9.38
10.81
-13.23%
14.73
8.19
79.85%
10.03
8.13
23.37%
Interest
0.06
0.24
-75.00%
0.10
0.46
-78.26%
0.10
0.50
-80.00%
0.10
0.84
-88.10%
Depreciation
17.78
13.18
34.90%
14.62
13.72
6.56%
13.26
13.54
-2.07%
13.31
13.29
0.15%
PBT
57.24
78.17
-26.77%
185.09
130.92
41.38%
99.32
100.09
-0.77%
133.29
113.18
17.77%
Tax
14.67
19.93
-26.39%
43.16
33.70
28.07%
25.23
25.53
-1.18%
34.59
28.69
20.56%
PAT
42.57
58.24
-26.91%
141.94
97.21
46.01%
74.09
74.55
-0.62%
98.70
84.49
16.82%
PATM
20.87%
26.99%
33.02%
30.48%
30.34%
30.96%
31.82%
32.21%
EPS
4.21
5.70
-26.14%
13.42
9.08
47.80%
7.26
7.41
-2.02%
9.15
7.74
18.22%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Net Sales
1,188.27
1,200.09
1,016.94
853.17
712.93
616.94
Net Sales Growth
14.49%
18.01%
19.20%
19.67%
15.56%
 
Cost Of Goods Sold
302.31
305.51
229.20
180.21
164.01
111.56
Gross Profit
885.96
894.57
787.74
672.96
548.92
505.38
GP Margin
74.56%
74.54%
77.46%
78.88%
76.99%
81.92%
Total Expenditure
701.82
693.24
584.75
504.59
439.01
289.01
Power & Fuel Cost
-
112.23
104.97
97.65
71.64
39.86
% Of Sales
-
9.35%
10.32%
11.45%
10.05%
6.46%
Employee Cost
-
138.93
123.05
110.28
95.69
69.47
% Of Sales
-
11.58%
12.10%
12.93%
13.42%
11.26%
Manufacturing Exp.
-
38.74
37.39
38.44
32.48
21.97
% Of Sales
-
3.23%
3.68%
4.51%
4.56%
3.56%
General & Admin Exp.
-
52.19
48.57
45.72
31.09
22.52
% Of Sales
-
4.35%
4.78%
5.36%
4.36%
3.65%
Selling & Distn. Exp.
-
34.55
33.11
23.70
21.44
13.36
% Of Sales
-
2.88%
3.26%
2.78%
3.01%
2.17%
Miscellaneous Exp.
-
11.09
8.46
8.59
22.66
10.26
% Of Sales
-
0.92%
0.83%
1.01%
3.18%
1.66%
EBITDA
486.45
506.85
432.19
348.58
273.92
327.93
EBITDA Margin
40.94%
42.23%
42.50%
40.86%
38.42%
53.15%
Other Income
47.82
44.45
33.78
35.31
23.42
13.81
Interest
0.36
1.04
3.18
9.80
6.13
1.05
Depreciation
58.97
54.37
53.59
54.03
50.05
27.52
PBT
474.94
495.88
409.19
320.05
241.16
313.17
Tax
117.65
122.91
104.46
81.93
62.59
77.83
Tax Rate
24.77%
24.79%
25.53%
25.60%
25.95%
24.85%
PAT
357.30
371.64
308.10
240.09
174.93
235.34
PAT before Minority Interest
357.30
371.64
308.10
240.09
174.93
235.34
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
30.07%
30.97%
30.30%
28.14%
24.54%
38.15%
PAT Growth
13.61%
20.62%
28.33%
37.25%
-25.67%
 
EPS
34.16
35.53
29.46
22.95
16.72
22.50

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Shareholder's Funds
1,812.72
1,526.65
1,290.00
1,103.22
999.37
Share Capital
10.46
10.46
10.46
9.51
9.51
Total Reserves
1,802.26
1,516.18
1,279.54
1,093.71
989.86
Non-Current Liabilities
37.47
31.91
32.13
54.40
77.43
Secured Loans
0.00
0.00
6.24
31.25
56.25
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
2.82
1.96
2.30
1.87
2.10
Current Liabilities
184.06
142.16
191.84
344.24
235.93
Trade Payables
113.04
94.44
93.80
83.11
46.40
Other Current Liabilities
54.97
38.32
61.57
65.98
53.58
Short Term Borrowings
0.38
0.00
0.00
4.34
5.10
Short Term Provisions
15.67
9.40
36.47
190.82
130.85
Total Liabilities
2,034.25
1,700.72
1,513.97
1,501.86
1,312.73
Net Block
794.69
575.32
592.98
572.98
546.22
Gross Block
1,097.16
828.31
792.80
718.85
645.33
Accumulated Depreciation
302.48
253.00
199.81
145.87
99.11
Non Current Assets
899.01
804.48
786.28
869.20
705.59
Capital Work in Progress
50.66
211.48
172.70
74.16
17.95
Non Current Investment
18.73
2.06
0.12
0.26
0.37
Long Term Loans & Adv.
12.01
12.81
11.61
220.99
140.61
Other Non Current Assets
22.93
2.81
8.87
0.82
0.45
Current Assets
1,135.24
896.23
727.70
632.67
607.15
Current Investments
316.54
243.70
136.93
73.47
140.99
Inventories
239.67
207.95
212.31
195.12
153.61
Sundry Debtors
521.65
349.61
273.76
232.17
177.52
Cash & Bank
1.18
47.02
43.45
88.93
60.82
Other Current Assets
56.19
26.82
45.57
32.53
74.22
Short Term Loans & Adv.
27.40
21.12
15.68
10.44
33.85
Net Current Assets
951.18
754.08
535.86
288.42
371.22
Total Assets
2,034.25
1,700.71
1,513.98
1,501.87
1,312.74

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Cash From Operating Activity
244.52
265.47
246.00
207.47
166.82
PBT
494.55
412.56
322.01
237.52
312.72
Adjustment
30.14
37.43
46.55
52.80
18.04
Changes in Working Capital
-170.76
-81.18
-52.29
-22.05
-88.76
Cash after chg. in Working capital
353.94
368.82
316.28
268.26
241.99
Interest Paid
0.00
0.00
0.00
0.00
0.00
Tax Paid
-109.42
-103.35
-70.28
-60.78
-75.18
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-159.99
-154.61
-157.95
-111.79
-195.21
Net Fixed Assets
-108.03
-74.29
-172.49
-130.77
Net Investments
-90.82
-106.65
-63.33
67.27
Others
38.86
26.33
77.87
-48.29
Cash from Financing Activity
-98.77
-99.21
-85.22
-100.16
31.12
Net Cash Inflow / Outflow
-14.24
11.64
2.83
-4.48
2.74
Opening Cash & Equivalents
15.14
3.50
0.67
5.14
2.41
Closing Cash & Equivalent
0.90
15.14
3.50
0.67
5.14

Financial Ratios

Standalone /

Consolidated
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Book Value (Rs.)
173.27
145.93
123.31
105.45
95.52
ROA
19.90%
19.17%
15.92%
12.43%
20.89%
ROE
22.26%
21.88%
20.06%
16.64%
26.60%
ROCE
29.62%
29.13%
26.70%
21.66%
33.01%
Fixed Asset Turnover
1.25
1.25
1.13
1.05
1.29
Receivable days
132.49
111.87
108.22
104.87
106.80
Inventory Days
68.07
75.42
87.15
89.27
78.34
Payable days
123.94
149.88
179.16
144.10
192.42
Cash Conversion Cycle
76.63
37.41
16.22
50.04
-7.28
Total Debt/Equity
0.00
0.00
0.02
0.05
0.09
Interest Cover
475.76
130.57
33.85
39.72
300.11

News Update:


  • Concord Biotech completes NAFDAC inspection at Valthera facility in Gujarat
    8th Oct 2025, 14:39 PM

    The inspection was conducted from October 06, 2025 to October 07, 2025

    Read More
  • EU-GMP authorities conduct inspection at Concord Biotech’s API facility in Limbassi
    21st Aug 2025, 15:58 PM

    The inspection was carried out from August 18, 2025 to August 21, 2025

    Read More
  • Concord Biotech - Quarterly Results
    8th Aug 2025, 16:44 PM

    Read More
  • Concord Biotech completes Russian GMP inspection
    28th Jul 2025, 15:00 PM

    The inspection was conducted at company's Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat

    Read More
  • Concord Biotech incorporates wholly owned subsidiary
    23rd Jul 2025, 12:30 PM

    The newly incorporated entity belongs to Biopharmaceutical Industry

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.